From: Modeling of α/β for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer
NTCP range
No. of patients
Observed Complications
Expected Complications
0.05-0.075
11
2
1
0.075-0.10
19
3
0.10-0.125
18
0.125-0.15
25
4
0.15-0.175
27
0.175-0.25
15